(Q24651090)

5

object named as

S Dueland

0 references

Gunnar Kvalheim

3

object named as

G Kvalheim

0 references

author name string

L J Mu

1

0 references

J A Kyte

2

0 references

S Aamdal

4

0 references

M Hauser

6

0 references

H Hammerstad

7

0 references

H Waehre

8

0 references

N Raabe

British Journal of Cancer

9

0 references

language of work or name

English

0 references

publication date

3 October 2005

0 references

published in

0 references

volume

93

0 references

issue

7

0 references

page(s)

749-56

0 references

cites work

The telomerase catalytic subunit is a widely expressed tumor-associated antigen recognized by cytotoxic T lymphocytes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361645

Dendritic cell immunotherapy for urological cancers using cryopreserved allogeneic tumour lysate-pulsed cells: a phase I/II study.

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361645

Autologous dendritic cell vaccines for non-small-cell lung cancer.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361645

Prostate cancer: a dynamic illness with shifting targets

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361645

Dendritic cells transfected with tumor RNA for the induction of antitumor CTL in colorectal cancer

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361645

Autologous dendritic cells transfected with prostate-specific antigen RNA stimulate CTL responses against metastatic prostate tumors

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361645

Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361645

Dendritic cell-based xenoantigen vaccination for prostate cancer immunotherapy

28 September 2017

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6602761

A comparison of two types of dendritic cell as adjuvants for the induction of melanoma-specific T-cell responses in humans following intranodal injection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6602761

Phase II randomized study of vaccine treatment of advanced prostate cancer (E7897): a trial of the Eastern Cooperative Oncology Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6602761

Allogeneic Dendritic Cells Fused with Tumor Cells: Preclinical Results and Outcome of a Clinical Phase I/II Trial in Patients with Metastatic Renal Cell Carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6602761

A protocol for generation of clinical grade mRNA-transfected monocyte-derived dendritic cells for cancer vaccines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6602761

Recurrence patterns after radical retropubic prostatectomy: clinical usefulness of prostate specific antigen doubling times and log slope prostate specific antigen

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6602761

Observations on the doubling time of prostate cancer. The use of serial prostate-specific antigen in patients with untreated disease as a measure of increasing cancer volume

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6602761

Hybrid cell vaccination for cancer immune therapy: first clinical trial with metastatic melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6602761

Vaccination of prostatectomized prostate cancer patients in biochemical relapse, with autologous dendritic cells pulsed with recombinant human PSA

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6602761

Human Dendritic Cells Transfected with RNA Encoding Prostate-Specific Antigen Stimulate Prostate-Specific CTL Responses In Vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6602761

Induction of Polyclonal Prostate Cancer-Specific CTL Using Dendritic Cells Transfected with Amplified Tumor RNA

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6602761

Telomerase mRNA-transfected dendritic cells stimulate antigen-specific CD8+ and CD4+ T cell responses in patients with metastatic prostate cancer

21 January 2018

1 reference

12 December 2020

Fusions of human ovarian carcinoma cells with autologous or allogeneic dendritic cells induce antitumor immunity

1 reference

12 December 2020

Allogeneic whole-tumour cell vaccination in the rat model of prostate cancer

1 reference

12 December 2020

Allogeneic whole-cell vaccine: a phase I/II study in men with hormone-refractory prostate cancer

1 reference

12 December 2020

Dendritic cells pulsed with pancreatic cancer total tumor RNA generate specific antipancreatic cancer T cells

1 reference

12 December 2020

Presentation of prostate tumor antigens by dendritic cells stimulates T-cell proliferation and cytotoxicity

1 reference

12 December 2020

Cytotoxic CD4+ and CD8+ T lymphocytes, generated by mutant p21-ras (12Val) peptide vaccination of a patient, recognize 12Val-dependent nested epitopes present within the vaccine peptide and kill autologous tumour cells carrying this mutation

1 reference

12 December 2020

Migration of human dendritic cells after injection in patients with metastatic malignancies

1 reference

12 December 2020

Preclinical full-scale evaluation of dendritic cells transfected with autologous tumor-mRNA for melanoma vaccination

1 reference

12 December 2020